

CORRECTION

Open Access



Correction to: Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex

Wanxia Fang^{1,2,3,4†}, Xiaofang Che^{1,2,3,4†}, Guohui Li⁵, Anhui Wang^{5,6}, Yizhe Wang⁷, Xiaonan Shi^{1,2,3,4}, Kezuo Hou^{1,2,3,4}, Xiaojie Zhang^{1,2,3,4}, Xiujuan Qu^{1,2,3,4*} and Yunpeng Liu^{1,2,3,4*}

Correction to: J Exp Clin Cancer Res 39, 82 (2020)
<https://doi.org/10.1186/s13046-020-01581-3>

Following publication of the original article [1], the authors identified some minor errors in Fig. 4, specifically:

- In Fig. 4c, left panel, the original figure presented a misused result of the analysis of Annexin V/7-AAD assay.

The corrected figure is given here. The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.

Author details

¹Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China. ²Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China. ³Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang 110001, China. ⁴Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang 110001, China. ⁵Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116024,

China. ⁶State Key Laboratory of Fine Chemicals, School of Chemistry, Dalian University of Technology, Dalian 116024, China. ⁷Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang 110001, China.

Published online: 07 December 2021

Reference

1. Fang W, Che X, Li G, et al. Sur-X, a novel peptide, kills colorectal cancer cells by targeting survivin-XIAP complex. *J Exp Clin Cancer Res.* 2020;39:82. <https://doi.org/10.1186/s13046-020-01581-3>.

The original article can be found online at <https://doi.org/10.1186/s13046-020-01581-3>.

*Correspondence: xiujuanqu@yahoo.com; ypliu@cmu.edu.cn

[†]Wanxia Fang and Xiaofang Che contributed equally to this work.

⁴ Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang 110001, China

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 4 Sur-X promoted necroptosis in colorectal cancer cells. **a** Cell morphology as determined by Giemsa staining. After treated by 10 μM Sur-X or Con, HCT116 cells were stained with Giemsa and those treated by adriamycin (10 μM for 12 h) was used as a positive control of apoptosis. Scale bar, 50 μm. Three independent experiments were performed. **b** The real-time detection of RFU (cell membrane damage, necrosis) in HCT116 cells over 6 h with indicated concentrations of Sur-X. NT, no treatment. Three independent experiments were performed. **c** HCT116 (top) and RKO (bottom) cells were treated by 10 μM Sur-X for 1, 3 and 6 h, or Con for 6 h, and analyzed by Annexin V/7-AAD assay (left panel). Quantification of 7-AAD positive cells, mean and SD of three independent experiments are shown (right panel). **d** HCT116 and RKO cells were treated by 10 μM Sur-X (0.5, 1, 3 and 6 h) or Con (6 h), the expressions of necroptosis-related proteins were detected by Western blot analysis. GAPDH was used as a loading control. NT, no treatment. Three independent experiments were performed. **e-f** Effect of Nec-1 s-pretreatment on Sur-X-induced necroptosis in HCT116 (top) and RKO (bottom) assessed by Annexin V/7-AAD assay (**e**). Quantification of Annexin V positive cells and quantification of 7-AAD positive cells in HCT116 (top) and RKO (bottom), mean and SD of three independent experiments are shown. NT, no treatment; Nec-1 s, cells were treated only by Nec-1 s; Sur-X, cells were treated by Sur-X (10 μM) for 6 h; Nec-1 s + Sur-X, cells were pretreated by Nec-1 s (50 μM) for 12 h and treated by Sur-X in combination with Nec-1 s for another 6 h (**f**). **g** Kinetic detection of apoptosis (RLU, phosphatidylserine and Annexin V binding) and necroptosis (RFU, membrane integrity) in HCT116 cells treated by 10 μM Sur-X was conducted simultaneously over 6 h. Three independent experiments were performed. **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$; ns, not significant